IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Running Oak Capital LLC

Running Oak Capital LLC boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 20.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,475 shares of the medical research company's stock after purchasing an additional 6,446 shares during the period. Running Oak Capital LLC's holdings in IQVIA were worth $8,902,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of IQV. AMF Tjanstepension AB purchased a new position in IQVIA during the 3rd quarter valued at about $148,096,000. Eagle Asset Management Inc. purchased a new position in IQVIA during the 3rd quarter valued at about $102,982,000. iA Global Asset Management Inc. increased its holdings in IQVIA by 1,225.3% during the 3rd quarter. iA Global Asset Management Inc. now owns 320,271 shares of the medical research company's stock valued at $63,013,000 after purchasing an additional 296,105 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in IQVIA by 2,765.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 271,316 shares of the medical research company's stock valued at $53,381,000 after purchasing an additional 261,848 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of IQVIA by 33.4% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,039,436 shares of the medical research company's stock worth $240,505,000 after acquiring an additional 260,271 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,000 shares of the firm's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares of the company's stock, valued at approximately $5,031,894. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares of the company's stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is owned by company insiders.

IQVIA Stock Down 4.6 %

IQV stock traded down $10.80 during midday trading on Thursday, hitting $222.14. The company's stock had a trading volume of 1,697,673 shares, compared to its average volume of 973,070. The company has a market cap of $40.32 billion, a PE ratio of 30.47, a P/E/G ratio of 2.24 and a beta of 1.52. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The firm's 50-day moving average is $244.56 and its 200-day moving average is $223.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to analysts' expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm's quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.54 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. StockNews.com upgraded IQVIA from a "hold" rating to a "buy" rating in a report on Friday, February 16th. Evercore ISI upped their target price on IQVIA from $255.00 to $265.00 and gave the stock a "market outperform" rating in a report on Thursday, February 15th. Robert W. Baird upped their target price on IQVIA from $226.00 to $251.00 and gave the stock a "neutral" rating in a report on Thursday, February 15th. BTIG Research assumed coverage on IQVIA in a report on Tuesday, February 13th. They set a "buy" rating and a $285.00 target price on the stock. Finally, Guggenheim downgraded IQVIA from a "buy" rating to a "neutral" rating in a report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $259.43.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.